The genetic testing company 23andMe filed for bankruptcy in March, after years of slowing sales, legal trouble, and a declining stock price. And now, the valuable trove of genetic data the company owns is for sale, sparking privacy concerns. 

On today’s Big Take, Bloomberg biotech reporter Gerry Smith traces the rise and fall of 23andMe, and bankruptcy reporter Jonathan Randles outlines what a possible sale could mean for millions of users’ genetic data.

Read more: Bankrupt 23andMe’s DNA Data Gets Sale Nod as Concerns Linger

The genetic testing company 23andMe filed for bankruptcy in March, after years of slowing sales, legal trouble, and a declining stock price. And now, the valuable trove of genetic data the company owns is for sale, sparking privacy concerns.&nbsp;
On today&rsquo;s Big Take, Bloomberg biotech reporter Gerry Smith traces the rise and fall of 23andMe, and bankruptcy reporter Jonathan Randles outlines what a possible sale could mean for millions of users&rsquo; genetic data.
Read more:&nbsp;<a href="https://www.bloomberg.com/news/articles/2025-03-26/bankrupt-23andme-s-dna-data-gets-nod-for-sale-as-concerns-linger">Bankrupt 23andMe&rsquo;s DNA Data Gets Sale Nod as Concerns Linger</a>

The Big Take from Bloomberg News brings you inside what’s shaping the world's economies with the smartest and most informed business reporters around the world. The context you need on the stories that can move markets. Every afternoon.

The Big Take from Bloomberg News brings you inside what’s shaping the world's economies with the smartest and most informed business reporters around the world. The context you need on the stories that can move markets. Every afternoon.

Big Take

DNA and Bankruptcy Collide With 23andMe

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/f419f212-856e-4c42-a37b-b2b501448027/transcript

Advertisement